Upcoming event

Protective effect of LCZ696 on kidney function after partial nephrectomy

Adjuvant therapy after surgical resection of nonmetastatic renal-cell carcinoma: One size does not fit all

Application of the KEYNOTE-564 trial results to real life population: Which patients with advanced kidney cancer should receive adjuvant pembrolizumab

Pembrolizumab outperforms tyrosine kinase inhibitors in the adjuvant therapy of patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis

Decision-making and management strategies for patients with bilateral synchronous non-metastatic renal masses: Insights from a multi-centre European dataset

The detrimental effect of frailty status on renal function recovery after partial nephrectomy – long-term results from a prospective surgical cohort

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

The Lancet Oncology, May 2022

LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data

Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426

What happens to the preserved renal parenchyma after clamped partial nephrectomy?

European Urology, May 2022

Next